Use of rescue medication
SECONDARY
Fewer dupilumab-treated patients required rescue medication compared to those given placebo during the 24-week studies (PRIME, 6.7% versus 21.1%; PRIME2, 7.7% versus 24.4%; non-multiplicity-controlled Results for additional efficacy endpoints are summarized in Extended Data Table This manuscript reports on all the multiplicity-controlled and pre-specified supportive endpoints included in the PRIME and PRIME2 trials. Additional pre-specified secondary and tertiary efficacy endpoints not reported in this manuscript are listed in the 